EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function

Ravi Retnakaran iD, Jiajie Pu, Alexandra Emery, Caroline K Kramer, Bernard Zinman iD

Diabetes, Obesity and Metabolism · 2023-09 · 25 (9) · 2473-2481

DOI: 10.1111/dom.15073 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.06.2023. Verfasst von Ravi Retnakaran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CIHR, Banting and Best Diabetes Centre, University of Toronto, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To identify baseline determinants of diabetes remission in response to short‐term insulin‐based therapy.

Methods

In this study, adult patients with type 2 diabetes (T2D) of less than 7 years duration were randomized to 8 weeks of treatment with (a) insulin glargine, (b) glargine + thrice‐daily lispro, or (c) glargine + twice‐daily exenatide, followed by 12 weeks of washout that enabled assessment of remission (defined as HbA1c < 6.5% after ≥ 3 months without glucose‐lowering therapy). At baseline, 8 weeks and washout, beta‐cell function was assessed with four measures: Insulin Secretion‐Sensitivity Index‐2 (ISSI‐2), insulinogenic index/Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR), ΔC‐peptide 0‐120 /Δglucose 0‐120 × Matsuda and Δinsulin secretion rate (ISR) 0‐120 /Δgluc 0‐120 × Matsuda.

Results

Diabetes remission was achieved in 31 of 90 participants (34.4%). Compared with their peers, those who went on to remission had lower HbA1c ( P < .001) and better beta‐cell function at baseline (all four measures P ≤ .01). The non‐remission and remission groups did not otherwise differ in baseline insulin sensitivity/resistance (Matsuda, HOMA‐IR), body mass index, duration of diabetes, pretrial diabetes medications or allocated insulin‐based therapy during the trial. On logistic regression analyses, each baseline measure of beta‐cell function emerged as a significant predictor of remission (log ISSI‐2: adjusted OR 4.41 [95% CI: 1.71‐11.34]; log insulinogenic index/HOMA‐IR: 2.21 [1.26‐3.89]; log ΔC‐peptide 0‐120 /Δglucose 0‐120 × Matsuda: 1.62 [1.00‐2.64]; log ΔISR 0‐120 /Δgluc 0‐120 × Matsuda: 1.87 [1.09‐3.23]). Similarly, higher baseline ISSI‐2 tertile predicted longer time to glycaemic relapse after cessation of the insulin‐based therapy (log‐rank P = .029).

Conclusion

Beta‐cell function is the dominant baseline pathophysiological determinant of the likelihood of achieving remission of diabetes in response to short‐term insulin‐based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceAdultHumansInsulinInsulin GlargineGlycated HemoglobinBlood GlucoseInsulin, Regular, Human

Stichwörter der Autor:innen

beta-cell functioninsulininsulin sensitivityremissiontype 2 diabetes

Substanzen

InsulinInsulin GlargineGlycated HemoglobinBlood GlucoseInsulin, Regular, Human

Autor:innen und Institutionen

  • Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Ravi Retnakaran, Bernard Zinman

Förderung

  • CIHR
  • Banting and Best Diabetes Centre, University of Toronto
  • Canadian Institutes of Health Research
  • Heart and Stroke Foundation of Canada

Zitieren

APA

Retnakaran, R., Pu, J., Emery, A., Kramer, C. K., & Zinman, B. (2023). Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function. Diabetes, Obesity and Metabolism, 25(9), 2473-2481. https://doi.org/10.1111/dom.15073

Vancouver

Retnakaran R, Pu J, Emery A, Kramer CK, Zinman B. Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function. Diabetes, Obesity and Metabolism. 2023;25(9):2473-2481. doi:10.1111/dom.15073

BibTeX
@article{Retnakaran2023,
  author = {Retnakaran, Ravi and Pu, Jiajie and Emery, Alexandra and Kramer, Caroline K and Zinman, Bernard},
  title = {Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {2473--2481},
  doi = {10.1111/dom.15073}
}
Kostenlos starten →